Onkologie. 2011:5(4):219-224

Cetuximab expands treatment options of head and neck cancer

Zdeněk Mechl1, Jana Neuwirthová2
1 Interní hematoonkologická klinika LF MU, Brno Bohunice
2 Klinika otolaryngologie a chirurgie hlavy a krku, FN MU Brno

Head and neck cancers are best managed in a multidisciplinary setting. Surgery, radiation therapy, chemotherapy and, more recently,

biologic therapy are often employed in various combinations in an attempt to eradicate both clinically apparent and occult disease.

This article aims to review the expanding role of novel targeted agent cetuximab, an epidermal growth factor receptor antagonist, and

review the current state of the data on the use of this drug in head and neck squamous cell carcinoma.

Keywords: head and neck cancer, targeted therapy, cetuximab

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mechl Z, Neuwirthová J. Cetuximab expands treatment options of head and neck cancer. Onkologie. 2011;5(4):219-224.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Specenier P, Vermorken JB. Cetuximab in the treatment of squamous cell carcinom of the head and neck. Expert Rev. Anticancer Ther 2011; 11(4): 511-524. Go to original source... Go to PubMed...
    2. Langer CJ, Gillison ML, Posner MR. Improving outcomes and quality of life in patients with head and neck cancer. Medscape CME Oncology 2010; 7: 16.
    3. Herchenhorn D, Dias FL, Virgas CM, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010; 78: 696-70. Go to original source... Go to PubMed...
    4. Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck cancer. CA A Cancer Journal for Clinicians 2008; 58(1): 32-49. Go to original source... Go to PubMed...
    5. Huang S, Armstrong EA, Benavente S, et al. Dual-agent molecular targeting of the epidermal growth factor receptor: combining anti-EGFR antibody with tyroxin kinase inhibitor. Cancer Res 2004; 64(15): 5355-5362. Go to original source... Go to PubMed...
    6. Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53(19): 4637-4642.
    7. Reeves TD, Hill EG, Armeson KE, et al. Cetuximab Therapy for Head and Neck Squamous Cell Carcinoma. A Systematic Review of the Data. Otolar. Head and Neck Surgery 2011; 144(5): 676-684. Go to original source... Go to PubMed...
    8. Robert T, Ezekiel MP, Spenser SA, et al. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19(13): 3234-3243. Go to original source... Go to PubMed...
    9. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin and concomitant boost radiotherapy for locoregionally advanced squamous cell head and neck cancer: a pilot Phase II study of a new combined modality paradigma. J Clin Oncol 2006; 24(7): 1072-1078. Go to original source... Go to PubMed...
    10. Balermpas P, Hambek M, Seitz O, et al. Combined cetuximab and re-irradiation for locoregional recurrent and inope rable squamous cell carcinoma of the head and neck. Strahlenther Oncol 2009; 185: 775-781. Go to original source... Go to PubMed...
    11. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C 225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7(5): 1204-1213.
    12. Baselga J, Pfister D, Cooper MR, et al. Phase I study of anti-epidermal growth factor receptor chimeric antibody C 255 alone and in combination with cisplatin. J Clin Oncol 2000; 18(4): 904-914. Go to original source... Go to PubMed...
    13. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor positive tumors. Cancer 2002; 94: 1593-1611. Go to original source... Go to PubMed...
    14. Bourhis J. New approaches to enhance chemotherapy in SCCHN. Ann Oncol 2005; 126: 20-24. Go to original source... Go to PubMed...
    15. Vermorken JB, Trigo J, Hitt T, et al. Open label, uncontrolled multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell cacinoma of the head ands neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177. Go to original source... Go to PubMed...
    16. Burtness B. Cetuximab and cisplatin for chemotherapyrefractory squamous cell cancer of the head and neck. J Clin Oncol 2005; 23(24): 5440-5442. Go to original source... Go to PubMed...
    17. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359(11): 1116-1127. Go to original source... Go to PubMed...
    18. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5 year survival data from a Phase III randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11(1): 21-28. Go to original source... Go to PubMed...
    19. Walsh I, Gilham C, Dunne M, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer. Radiother Oncol 2011; 98(1): 38-41. Go to original source... Go to PubMed...
    20. Merlano M, Russi E, Benasso M, et al. Cisplatin-based chemoradiation plus cetuximab on locally advanced head and neck cancer: a Phase II clinical study. Ann Oncol 2010; 22(3): 712-714. Go to original source... Go to PubMed...
    21. Kao J, Genden EM, Gupta V, et al. Phase II trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation. Therapy for locally advanced head and neck cancer. Cancer 2011; 117(2): 318-326. Go to original source... Go to PubMed...
    22. Licitra L, Bergamini C, Olmi P, et al. Phase I study of concurrent pemetrexed, cetuximab and radiation therapy with or without cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21(8a): 1025.
    23. Kotsakis A, Heron DF, Kubicek GJ, et al. Phase II randomised trial of radiotherapy cetuximab and pemetrexed with or without bevacizumab in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2010; 28(15): TPS 264. Go to original source...
    24. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high risk squamous cell carcinoma of the head and neck. NEJM 2004; 350(19): 1937-1944. Go to original source... Go to PubMed...
    25. Mesia R, Rueda A, Vera R, et al. Is there a role for adjuvant cetuximab after radiotherapy plus cetuximab in patients with locally advanced squamous cell carcinoma of the oropharynx? A Phase II randomised trial. 2010; 28(15s): 5534. Go to original source...
    26. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head an neck. J Clin Oncol 2005; 23(24): 5568-5577. Go to original source... Go to PubMed...
    27. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23(24): 5578-5587. Go to original source... Go to PubMed...
    28. Bourhis J, Riveraq F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24(18): 2866-2872. Go to original source... Go to PubMed...
    29. Burtness B. Cetuximab and cisplatin for chemotherapy refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23(24): 5440-5442. Go to original source... Go to PubMed...
    30. Vermorken JB, Remenar E, Carla Van Herpen, et al. Standard cisplatin/infusional 5- fluorouracil vs. docetaxel plus PF as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2004; 22(Suppl): Abst 490. Go to original source...
    31. Argiris A. Karamouzis MV. Empovering induction therapy for locally advanced head and neck cancer. Ann Oncol 2011; 22: 773-781. Go to original source... Go to PubMed...
    32. Tannock I. Cell kinetics and chemotherapy, a critical review. Cancer Trea Rep 1978; 62: 1117-1133.
    33. Argiris AE, Gibbon MK, Heron DE, et al. Phase II trial of neoadjuvant docetaxel, cisplatin and cetuximab followed by concurrent radiation, cisplatin and Erbitux in locally advanced head and neck cancer. J Clin Oncol 2008; 26: Abst 6002. Go to original source... Go to PubMed...
    34. Mesia R, Vasquewz SH, Grau JJ, et al. A single arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin and 5-fluorouracil as induction chemotherapy in patients with unresectable SCCHN. J Clin Oncol 2009; 27: Abst 6015. Go to original source... Go to PubMed...
    35. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8-14. Go to original source... Go to PubMed...
    36. Wanebo HJ, Ghebremichael M, Burtness B, et al. Phase II evaluation of cetuximab combined with induction paclitaxel and carboplatin followed by C 225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck. J Clin Oncol 2007; 25: Abst 6015. Go to original source...
    37. Ferrit RL, et al. Induction with TPE (docetaxel, cisplatin adn cetuximab) followed by concurrent radiotherapy, cisplatin and cetuximab in patients with locally advanced head and neck cancer. ASCO 2010; Abst 5515. Go to original source...
    38. Mercke C, et al. Toxicity and one-year control after induction chemotherapy and biotherapy for locally advanced, non resectable cancer of the head and neck carcinoma. ASCO 2010; Abst 5581. Go to original source...
    39. Jordan W, et al. Induction with TPF and radioimmunotherapy in the therapy of advanced cancer of the head and neck. ASCO 2010; Abst 5514. Go to original source...
    40. Tsousou J, et al. Neoadjuvant chemotherapy with cisplatin, docetaxel and cetuximab followed by chemoradiotherapy in locally advanced cancer of the head and neck. ASCO 2010; Abst 6025.
    41. Lefebre JL, Pointreau Y, Rolland F, et al. Sequential chemotherapy for larynx preservation: preliminary results of the randomized Phase II TREMPLIN study. J Clin Oncol 2009; 27(15): 6010. Go to original source...
    42. Gillison M. Evolving treatment paradigm in the management of oropharyngeal cancer. The Lancet Conference, HPV and cancer. Amsterdan 2010; Abst 33.
    43. Mulcahy N. HPV status is prognostic in oropharyngeal cancer. ASCO 2010; Abst 5507.
    44. Specenier PM, Vermorken JB. Targeted therapies in head and neck cancer. Target Oncol 2007; 2(2): 73-88. Go to original source...
    45. Vermorken JB. A new look at induction chemotherapy in locally advanced head and neck cancer The Oncologist. 2010; 15(Suppl): 1-2. Go to original source... Go to PubMed...
    46. Budach V, et al. ESMO 2010; Abst 1031.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.